Suppr超能文献

[F]FMCH PET/CT生物标志物及相似性分析以完善寡转移前列腺癌的定义

[F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer.

作者信息

Sollini Martina, Bartoli Francesco, Cavinato Lara, Ieva Francesca, Ragni Alessandra, Marciano Andrea, Zanca Roberta, Galli Luca, Paiar Fabiola, Pasqualetti Francesco, Erba Paola Anna

机构信息

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milan, Italy.

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

出版信息

EJNMMI Res. 2021 Nov 27;11(1):119. doi: 10.1186/s13550-021-00858-8.

Abstract

BACKGROUND

The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions similarity in oligometastatic and plurimetastatic PCa, comparing the two most used definitions of oligometastatic disease.

METHODS

PCa patients eligible for [F]FMCH PET/CT presenting biochemical failure after first-line curative treatments were invited to participate in this prospective observational trial. PET/CT images of 92 patients were visually and quantitatively analyzed. Each patient was classified as oligometastatic or plurimetastatic according to the total number of detected lesions (up to 3 and up to 5 or > 3 and > 5, respectively). Univariate and intra-patient lesions' similarity analysis were performed.

RESULTS

[F]FMCH PET/CT identified 370 lesions, anatomically classified as regional lymph nodes and distant metastases. Thirty-eight and 54 patients were designed oligometastatic and plurimetastatic, respectively, using a 3-lesion threshold. The number of oligometastic scaled up to 60 patients (thus 32 plurimetastatic patients) with a 5-lesion threshold. Similarity analysis showed high lesions' heterogeneity. Grouping patients according to the number of metastases, patients with oligometastatic PCa defined with a 5-lesion threshold presented lesions heterogeneity comparable to plurimetastic patients. Lesions within patients having a limited tumor burden as defined by three lesions were characterized by less heterogeneity.

CONCLUSIONS

We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.

摘要

背景

影像衍生生物标志物在复发性寡转移前列腺癌(PCa)中的作用尚未得到探索。本文旨在评估[F]FMCH PET/CT放射组学分析在原发性根治性治疗后复发性PCa患者中的应用。具体而言,我们测试了寡转移和多转移PCa患者体内病变的相似性,比较了两种最常用的寡转移疾病定义。

方法

邀请一线根治性治疗后出现生化失败且符合[F]FMCH PET/CT检查条件的PCa患者参加这项前瞻性观察性试验。对92例患者的PET/CT图像进行了视觉和定量分析。根据检测到的病变总数(分别最多为3个和最多为5个或>3个和>5个)将每位患者分类为寡转移或多转移。进行了单变量和患者体内病变相似性分析。

结果

[F]FMCH PET/CT识别出370个病变,解剖学上分类为区域淋巴结和远处转移。使用3个病变阈值时,分别有38例和54例患者被定义为寡转移和多转移。使用5个病变阈值时,寡转移患者数量增至60例(因此多转移患者为32例)。相似性分析显示病变具有高度异质性。根据转移灶数量对患者进行分组,使用5个病变阈值定义的寡转移PCa患者的病变异质性与多转移患者相当。由3个病变定义的肿瘤负荷有限的患者体内的病变异质性较小。

结论

我们发现,病变数最多为5个的患者与多转移患者之间存在相当的异质性,而病变数最多为3个的患者比多转移患者的异质性小,两组具有不同的细胞表型。我们的结果支持使用3个病变阈值来定义寡转移PCa。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ece7/8627538/6591e070f491/13550_2021_858_Fig1_HTML.jpg

相似文献

2
[F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer.
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):185-191. doi: 10.1007/s00259-019-04482-6. Epub 2019 Oct 16.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
9
Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results.
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):815-20. doi: 10.1007/s00259-007-0685-x. Epub 2008 Jan 6.

引用本文的文献

3
Oligometastatic Prostate Cancer: Current Status and Future Challenges.
J Nucl Med. 2022 Nov;63(11):1628-1635. doi: 10.2967/jnumed.121.263124.
4
The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease.
Cancers (Basel). 2022 Apr 18;14(8):2046. doi: 10.3390/cancers14082046.

本文引用的文献

1
Artificial intelligence and hybrid imaging: the best match for personalized medicine in oncology.
Eur J Hybrid Imaging. 2020 Dec 9;4(1):24. doi: 10.1186/s41824-020-00094-8.
2
Methodological framework for radiomics applications in Hodgkin's lymphoma.
Eur J Hybrid Imaging. 2020 Jun 1;4(1):9. doi: 10.1186/s41824-020-00078-8.
3
Metabolic regulation of prostate cancer heterogeneity and plasticity.
Semin Cancer Biol. 2022 Jul;82:94-119. doi: 10.1016/j.semcancer.2020.12.002. Epub 2020 Dec 5.
4
Climbing the steps of the evidence-based medicine pyramid: highlights from Annals of Nuclear Medicine 2019.
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1293-1301. doi: 10.1007/s00259-020-05073-6. Epub 2020 Nov 4.
7
9
Imaging for Metastasis in Prostate Cancer: A Review of the Literature.
Front Oncol. 2020 Jan 31;10:55. doi: 10.3389/fonc.2020.00055. eCollection 2020.
10
Quantitative imaging biomarkers in nuclear medicine: from SUV to image mining studies. Highlights from annals of nuclear medicine 2018.
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2737-2745. doi: 10.1007/s00259-019-04531-0. Epub 2019 Nov 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验